Natera

YTD

ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

CEO

Stephen Leonard Chapman

CEOStephen Leonard Chapman

Employees

6,140

Employees6,140

Headquarters

Austin, Texas

HeadquartersAustin, Texas

Founded

2003

Founded2003

Employees

6,140

Employees6,140

NTRA Key Statistics

Market cap

57.80B

Market cap57.80B

Price-Earnings ratio

-291.85

Price-Earnings ratio-291.85

Dividend yield

—

Dividend yield—

Average volume

1.60M

Average volume1.60M

High today

$405.00

High today$405.00

Low today

$398.45

Low today$398.45

Open price

$400.01

Open price$400.01

Volume

25.31K

Volume25.31K

52 Week high

$437.41

52 Week high$437.41

52 Week low

$181.00

52 Week low$181.00

Stock Snapshot

Natera(NTRA) stock is priced at $400.97, giving the company a market capitalization of 57.8B. It carries a P/E multiple of -291.85.

As of 2026-10-20, Natera(NTRA) stock has fluctuated between $398.45 and $405.00. The current price stands at $400.97, placing the stock +0.6% above today's low and -1.0% off the high.

The Natera(NTRA)'s current trading volume is 25.31K, compared to an average daily volume of 1.6M.

In the last year, Natera(NTRA) shares hit a 52-week high of $437.41 and a 52-week low of $181.00.

NTRA News

Simply Wall St 1d

Natera Gains Fresh Clinical Backing As Fair Value Debate Stays Open

Natera (NTRA) has moved back into focus after its Signatera Genome technology was featured in 20 abstracts at the 2026 ESMO Congress, along with fresh FDA Break...

TipRanks 1d

Natera price target raised to $500 from $375 at Canaccord

Canaccord raised the firm’s price target on Natera (NTRA) to $500 from $375 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results...

TipRanks 2d

Natera presents 20 abstracts at ESMO 2026

Natera (NTRA) announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology, ESMO, Annual Congress, t...

Analyst ratings

88%

of 25 ratings

Buy

88%

Hold

Sell

More NTRA News

Simply Wall St 5d

Does FDA Breakthrough Status Change The Bull Case For Natera Stock?

Natera reported a cluster of cancer-focused milestones, including FDA Breakthrough Device designation for its multi-cancer early detection assay and fresh clini...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.